Denali Therapeutics Inc. Common Stock (DNLI)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.14 (+0.56%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Denali Therapeutics Inc. Common Stock (DNLI)
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Key Insights

Critical company metrics and information
  • Share Price

    $25.10
  • Market Cap

    $3.61 Billion
  • Total Outstanding Shares

    143.92 Million Shares
  • Total Employees

    390
  • Dividend

    No dividend
  • IPO Date

    December 8, 2017
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Homepage

    https://www.denalitherapeutics.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow$-57.38 Million
Net Cash Flow From Operating Activities$-362.64 Million
Net Cash Flow From Financing Activities$493.18 Million
Net Cash Flow From Investing Activities$-187.92 Million
Net Cash Flow From Operating Activities, Continuing$-362.64 Million
Net Cash Flow From Investing Activities, Continuing$-187.92 Million
Net Cash Flow From Financing Activities, Continuing$493.18 Million
Net Cash Flow, Continuing$-57.38 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Revenues$14.54 Million
Net Income/Loss Attributable To Parent$-427.49 Million
Net Income/Loss$-427.49 Million
Operating Expenses$504.60 Million
Income/Loss From Continuing Operations After Tax$-427.49 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Income/Loss From Continuing Operations Before Tax$-308.02 Million
Benefits Costs and Expenses$322.56 Million
Preferred Stock Dividends And Other Adjustments$0.00
Diluted Average Shares$162.88 Million
Research and Development$404.46 Million
Other Operating Expenses$100.15 Million
Operating Income/Loss$-490.07 Million
Diluted Earnings Per Share$-2.76
Net Income/Loss Available To Common Stockholders, Basic$-427.49 Million
Basic Average Shares$328.87 Million
Basic Earnings Per Share$-2.76
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Costs And Expenses$504.60 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Fixed Assets$50.82 Million
Accounts Payable$9.59 Million
Liabilities$135.52 Million
Noncurrent Liabilities$48.42 Million
Other Non-current Assets$534.35 Million
Equity Attributable To Noncontrolling Interest$0.00
Equity Attributable To Parent$1.32 Billion
Current Assets$868.84 Million
Assets$1.45 Billion
Equity$1.32 Billion
Liabilities And Equity$1.45 Billion
Noncurrent Assets$585.17 Million
Current Liabilities$87.09 Million
Wages$14.87 Million
Other Current Liabilities$62.63 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.